Literature DB >> 16227370

ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.

J M van Dieren, A J van Vuuren, J G Kusters, E E S Nieuwenhuis, E J Kuipers, C J van der Woude.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16227370      PMCID： PMC1774739     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

Authors:  Satoshi Sumi; Anthony M Marinaki; Monica Arenas; Lynette Fairbanks; Monsor Shobowale-Bakre; David C Rees; Swee Lay Thein; Azhar Ansari; Jeremy Sanderson; Ronney A De Abreu; H Anne Simmonds; John A Duley
Journal:  Hum Genet       Date:  2002-08-15       Impact factor: 4.132

2.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

3.  Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.

Authors:  L Lennard; J A Van Loon; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

4.  TPMT in the treatment of Crohn's disease with azathioprine.

Authors:  L Lennard
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

5.  Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

Authors:  Anthony M Marinaki; Azhar Ansari; John A Duley; Monica Arenas; Satoshi Sumi; Cathryn M Lewis; El-Monsor Shobowale-Bakre; Emilia Escuredo; Lynette D Fairbanks; Jeremy D Sanderson
Journal:  Pharmacogenetics       Date:  2004-03
  5 in total
  12 in total

1.  Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.

Authors:  Katerina Wroblova; Michal Kolorz; Marian Batovsky; Vladimir Zboril; Jana Suchankova; Milan Bartos; Boris Ulicny; Igor Pav; Ladislava Bartosova
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

2.  Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

Authors:  Elena I Stepchenkova; Elena R Tarakhovskaya; Kathryn Spitler; Christin Frahm; Miriam R Menezes; Peter D Simone; Carol Kolar; Luis A Marky; Gloria E O Borgstahl; Youri I Pavlov
Journal:  J Mol Biol       Date:  2009-07-23       Impact factor: 5.469

3.  Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis.

Authors:  Evaggelia Barba; Panagiota I Kontou; Ioannis Michalopoulos; Pantelis G Bagos; Georgia G Braliou
Journal:  Pharmacogenomics J       Date:  2022-01-17       Impact factor: 3.550

4.  Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant.

Authors:  Irina S-R Waisertreiger; Miriam R Menezes; James Randazzo; Youri I Pavlov
Journal:  J Nucleic Acids       Date:  2010-09-26

5.  Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.

Authors:  G Stocco; M H Cheok; K R Crews; T Dervieux; D French; D Pei; W Yang; C Cheng; C-H Pui; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

6.  Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.

Authors:  Kan Uchiyama; Makoto Nakamura; Takahiro Kubota; Tateki Yamane; Kiyotaka Fujise; Hisao Tajiri
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

7.  TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients.

Authors:  Mateusz Kurzawski; Krzysztof Dziewanowski; Agnieszka Lener; Marek Drozdzik
Journal:  Eur J Clin Pharmacol       Date:  2009-02-20       Impact factor: 2.953

8.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

Review 9.  Current stage in inflammatory bowel disease: What is next?

Authors:  Gonzalo Jesús Gómez-Gómez; Ángeles Masedo; Carmen Yela; Maria del Pilar Martínez-Montiel; Begoña Casís
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 10.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.